Innovative smart pill bottles significantly enhance adherence to oral adjuvant endocrine therapy in early-stage breast cancer ...

T-DXd regimens improved pathologic complete response and safety profiles compared to ddAC-THP in high-risk, HER2-positive early breast cancer. Patient-reported outcomes showed better physical ...

Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following ...

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) ...

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

Today at the San Antonio Breast Cancer Symposium (SABCS), researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and ...

Some experts believe the cancer label can be inappropriate for certain low-risk conditions and advocate dropping the C-word.

Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers.

Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreasttm, a novel multi-omic ...

Male breast cancer is rare, but studies suggest it's more common — and more lethal — among veterans. Yet the Veterans Administration is making it harder for veterans with breast cancer to get care.

The largest international gathering of breast cancer researchers returns to San Antonio and continues to lead as the hub for scientific breakthroughs. Mays Cancer Center at UT Health San Antonio, in ...